Tagged with ONS

USA Philip Macnabb serves as Chief Executive Officer of Curia, bringing 25 years of private equity-backed healthcare experience to his first venture into the CDMO sector. Joining in March 2023, Macnabb leads a globally diversified CDMO with 20 facilities spanning drug discovery through commercial manufacturing, serving predominantly biotech customers whilst maintaining…

Argentina Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical market and the high-cost speciality products segment, a feat that requires markedly different capabilities. Leveraging full vertical integration and a…

France Norgine is redefining what a mid-sized European specialist can achieve, shifting from its gastroenterology heritage into a broader mix of consumer health, women’s health and rare diseases. These changes are taking shape across the organisation, with France playing an important role under Cyril Tavier’s leadership, from implementing new omnichannel models…

Europe Cancer is one of Europe’s most urgent health challenges. Responsible for 23 percent of all mortality on the continent, the burden is particularly acute outside the EU5, where access timelines vary dramatically. Countries in Central and Eastern Europe, for example, face some of Europe’s highest cancer mortality rates, largely due…

USA Global pharma is rushing to relocate manufacturing to the US. To reduce dependence on foreign manufacturing sources – most notably from its main economic adversary, China – the Trump administration is putting pressure on pharma to situate production on US soil. This pressure is predominantly taking the form of economic…

France At the helm of EG Labo (STADA Group), Tiago Bartolomeu is steering one of France’s leading accessible medicine players through a period of renewal and ambition. With a clear focus on expanding access through generics, biosimilars, and consumer health, he reflects on the company’s growth strategy, its role as a…

Brazil As one of Brazil’s leading pharmaceutical powerhouses, CIMED has redefined what it means to be both national and innovative. Built on a fully verticalised model that spans from R&D to direct distribution, the family-owned company has transformed the pharmacy landscape while empowering thousands of independent retailers across the country. Now,…

Denmark Public Health Reimagined Denmark’s total health expenditure as a share of GDP has increased moderately over the past decade with the country spending 278 billion KKR (37.2 billion euros) in 2024, of which 83% was financed directly from government health schemes. Yet despite the country’s well-earned reputation for delivering high…

France Alexis Genin, CEO of Brain & Mind, discusses the strategic vision behind France’s first national hub for neuroscience product development. Established to overcome the fragmented landscape in neuroscience innovation, Brain & Mind unites over 40 partners across industry, research, and investment. Under Genin’s leadership, the organization has focused on closing…

Switzerland Urs Indermühle sees 2025 shaped by three big shifts and two urgent risks: R&D is now mostly sourced externally (just 35 percent developed in‑house), forcing pharma to master licensing and ecosystem partnerships; Asia, especially China, has become a serious innovation hub, making global IP and footprint strategies a priority; and…

Switzerland Doetsch Grether may be 126 years old, but it is anything but traditional. With a portfolio that spans pharmaceuticals, consumer health, and retail – an uncommon mix for a company of its size – the Swiss firm is doubling down on focused expansion, values-driven culture, and long-term partnerships. For Wannhoff,…

Denmark Helene Probst, Health Director, Danish Regions, outlines Denmark’s healthcare reform as a major shift from hospital-centric care to a primary care-focused system, driven by workforce shortages and an ageing population. Key changes include redistributing responsibilities to regions, creating health councils, and redefining the GP role to better serve local and…